Using glucocorticoids, rituzimab, or certain immunosuppressants to treat connective tissue diseases is associated with greater risks for severe COVID-19-related outcomes.

This feature is a deep dive into the challenges of defining and treating Difficult-to-Treat Rheumatoid Arthritis (D2T-RA).

Think rheumatoid arthritis only affects the elderly? Or that exercise makes it worse? Time to bust these myths! We got in ...

The vagus nerve, a complex bundle of 200,000 fibers connecting the brain to vital organs, has remained a medical enigma for ...

AnaptysBio stock whipsawed Wednesday despite promising results for its experimental rheumatoid arthritis treatment.

AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...

Patients with late-onset rheumatoid arthritis experienced greater functional impairment over 5 years, compared against those with younger-onset disease.

Carolyn Adelsten woke up feeling like something was in her eye and it wouldn't come out. She visited an eye specialist, got a diagnosis of mild dry eye disease and was told to ...

Protein disulfide isomerases (PDIs) are essential enzymes that facilitate the proper folding of proteins and maintain protein quality within the endoplasmic reticulum.

A new Swedish study has, for the first time, shown a link between rheumatoid arthritis (RA) and cognitive decline in dementia ...

Understand RA from early to advanced stages. Explore symptoms, treatments, and lifestyle tips to manage rheumatoid arthritis ...

The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab-anoh), a biosimilar to Actemra ® (tocilizumab), in both intravenous (IV) and subcutaneous (SC) formulations.